Hybridomas, which produce monoclonal antibodies, are made by fusing cells of the immune system with B lymphocytes and myeloma cells.
<h3>
What are Hybridomas?</h3>
- Large-scale production of monoclonal antibodies is made possible through hybridoma technology.
- An antigen that triggers an immune response is first injected into a mammal to begin the process.
- A specific sort of white blood cell called a B cell makes antibodies that bind to the antigen that has been injected.
- These antibody-producing B-cells are then removed from the animal and combined with immortal B cell cancer cells, or myeloma, to create a hybrid cell line known as a hybridoma.
- It possesses both longevity and procreative capacity of the myeloma and the antibody-producing capacity of the B-cell.
Hence, the creation of hybridomas, which result in the production of monoclonal antibodies, involves fusing immune system cells with B lymphocytes and myeloma cells.
To learn more about Hybridomas refer to:
brainly.com/question/15189667
#SPJ4
Answer:
I would pray and give my life to the lord so that if worst comes to worst you can get to heaven. I don't know what's going to happen because I personally have never gone through anything near to what you're going through now. I will definitely keep you in my prayers. I'm so sorry about what you're going through and cannot imagine the things you are thinking.
Answer:
Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%. In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy. DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic. In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.
Keywords: Absorption, adverse drug reaction, distribution, drug-drug interactions, excretion, metabolism, poly-therapy
Answer:
The muscles of the intestinal wall contract slowly and involuntarily.
patient with iron deficiency anemia will have low hemoglobin levels as well as microcytic and hypochromic RBCs, according to the results of a complete blood count. Typically, the reticulocyte count is normal or slightly increased.
<h3>what is
iron deficiency anemia?</h3>
- Insufficient iron is the cause of iron deficiency anemia.
- Your body needs iron to produce enough of a component in red blood cells that makes it possible for them to carry oxygen (hemoglobin).
- Thus, iron deficiency anemia may make you feel lethargic and breathless.
<h3>How serious is iron deficiency anemia?</h3>
- Iron-deficiency anemia can have major side effects, including fatigue, headaches, restless legs syndrome, heart issues, problems during pregnancy, and delays in a child's development.
- Additionally, iron deficiency anemia can worsen other chronic illnesses or render their therapies ineffective.
<h3>What three levels of iron deficiency are there?</h3>
Deficiency in Iron Has 3 Stages
- Stage 1: A decrease in the body's overall iron content. A decrease in serum ferritin serves as an indicator of this stage.
- Stage 2 Reduced red blood cell production. This stage develops when there is not enough iron available to sustain the production of red blood cells.
- Stage 3 Iron deficiency anemia.
learn more about Iron deficiency anemia here
<u>brainly.com/question/866200</u>
#SPJ4
